https://scholars.lib.ntu.edu.tw/handle/123456789/517534
標題: | Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment | 作者: | Yeh N.-L. Hsu C.-Y. TSEN-FANG TSAI HSIEN-YI CHIU |
公開日期: | 2019 | 出版社: | Springer International Publishing | 卷: | 39 | 期: | 12 | 起(迄)頁: | 1195-1203 | 來源出版物: | Clinical Drug Investigation | 摘要: | Background and Objective: Immunotherapy could change the complex host-microbial interactions. We aimed to investigate the dynamics of gut microbiome in response to secukinumab [an interleukin (IL)-17 inhibitor] and ustekinumab (an IL-12/23 inhibitor) therapy and its association with treatment response in psoriasis. Methods: This observational, longitudinal study collected a total of 114 fecal samples from 12 healthy controls and 34 patients with psoriasis at baseline and 3 and 6?months after secukinumab (n = 24) or ustekinumab treatment (n = 10) and gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA. Results: Secukinumab treatment causes more profound alterations in gut microbiome, including increases in the relative abundance of phylum Proteobacteria and decreases in Bacteroidetes and Firmicutes, than ustekinumab treatment. The relative abundance of family Pseudomonadaceae, family Enterobacteriaceae and order Pseudomonadales also increased significantly following secukinumab therapy. In contrast, there was no significant change in gut microbiome composition following ustekinumab treatment, and only genus Coprococcus significantly increased after 6?months of ustekinumab therapy. Moreover, we observed significant differences in baseline gut microbiome between responders and non-responders to secukinumab treatment. Conclusion: These results indicate that gut microbiome is altered differently after anti-IL17 and anti-IL12/23 treatment. Secukinumab (anti-IL17) therapy is associated with distinct and more profound gut microbiome shifts than ustekinumab therapy (anti-IL 12/23) in patients with psoriasis. Moreover, gut microbiome would serve as potential biomarkers of response to secukinumab treatment. ? 2019, Springer Nature Switzerland AG. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073967425&doi=10.1007%2fs40261-019-00849-7&partnerID=40&md5=3c134f4568f054e5919fd3387d139cb5 https://scholars.lib.ntu.edu.tw/handle/123456789/517534 |
ISSN: | 1173-2563 | DOI: | 10.1007/s40261-019-00849-7 | SDG/關鍵字: | genomic DNA; RNA 16S; secukinumab; ustekinumab; interleukin 12; interleukin 17; interleukin 23; monoclonal antibody; secukinumab; ustekinumab; Aeromonas; Article; Bacteroidetes; controlled study; Coprococcus; Enterobacteriaceae; Firmicutes; gene sequence; host microbe interaction; human; intestine flora; longitudinal study; major clinical study; next generation sequencing; nonhuman; observational study; priority journal; Proteobacteria; Pseudomonadaceae; Pseudomonadales; psoriasis; Psoriasis Area and Severity Index; psoriatic arthritis; adult; drug effect; female; intestine flora; male; microbiology; middle aged; psoriasis; Adult; Antibodies, Monoclonal, Humanized; Female; Gastrointestinal Microbiome; Humans; Interleukin-12; Interleukin-17; Interleukin-23; Longitudinal Studies; Male; Middle Aged; Psoriasis; Ustekinumab |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。